Konferanseforedrag

• Helge Wiestad; Olav Vikmoen; Maria Ranes et al. (2024). EFFECTS OF HIGH VS. MODERATE INTENSITY EXERCISE DURING (NEO-)ADJUVANT CHEMOTHERAPY ON CARDIORESPIRA- TORY FITNESS, MITOCHONDRIAL ENZYMES AND CAPILLARIES IN WOMEN WITH BREAST CANCER. (ekstern lenke)
• Tor Helge Wiestad; Olav Vikmoen; Maria Ranes et al. (2023). EFFECTS OF HIGH VS. MODERATE INTENSITY COMBINED STRENGTH AND ENDURANCE TRAINING DURING CHEMOTHERAPY ON CARDIORESPIRATORY FITNESS, MUSCLE STRENGTH AND ENDURANCE IN WOMEN WITH BREAST CANCER. (ekstern lenke)

Vitenskapelig artikkel

• Jon Espen Dale; Sigrunn Sebjørnsen; Sabine Maria Leh et al. (2016). Multimodal therapy is feasible in elderly anal cancer patients. (ekstern lenke)
• Hanne Skjerven Bersvendsen; Hege Sagstuen Haugnes; Unn-Merete Fagerli et al. (2019). Lifestyle behavior among lymphoma survivors after high-dose therapy with autologous hematopoietic stem cell transplantation, assessed by patient-reported outcomes. (ekstern lenke)
• Harald Holte; Sirpa Leppä; Mikaela Bjørkholm et al. (2013). Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. (ekstern lenke)
• Erling Dahl Borkamo; Olav Dahl; Ove Bruland et al. (2008). Global gene expression analyses reveal changes in biological processes after hyperthermia in a rat glioma model. (ekstern lenke)
• Øystein Fluge; Olav Mella (2009). Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrome: a preliminary case series. (ekstern lenke)
• Øystein Fluge; Hanne Thurmer (2016). Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome. (ekstern lenke)
• Marius Stensland; Jan Klos; Øystein Fluge et al. (2017). Extranodal NK/T-cell lymphoma, nasal type, primarily involving ovary. (ekstern lenke)
• Øystein Fluge; Olav Mella; Ove Bruland et al. (2016). Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome.. (ekstern lenke)
• Elisa J. Pulczynski; Outi Kuittinen; Martin Erlanson et al. (2015). Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group. (ekstern lenke)
• Cecilie Svanes; Ernst Omenaas; Geir Egil Eide et al. (1998). Hospitalization for lung disease in early childhood and asthma symptoms in young adulthood. (ekstern lenke)
• Leo Meriranta; Amjad Alkodsi; Annika Pasanen et al. (2021). Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma. (ekstern lenke)
• Øystein Fluge; Bård Mannsåker; Anders Torp et al. (2017). Consolidative radiotherapy to residual masses after chemotherapy is associated with improved outcome in diffuse large B-cell lymphoma. A retrospective, population-based study. (ekstern lenke)
• Line Sagerup Bjorland; Oystein Fluge; Bjornar Gilje et al. (2021). Treatment approach and survival from glioblastoma: Results from a population-based retrospective cohort study from Western Norway. (ekstern lenke)
• Kari Sørland; Miriam Kristine Sandvik; Ingrid Gurvin Rekeland et al. (2021). Reduced Endothelial Function in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome-Results From Open-Label Cyclophosphamide Intervention Study. (ekstern lenke)
• Minna Taskinen; Riku Louhimo; Satu Koivula et al. (2014). Deregulation of COMMD1 is associated with poor prognosis in diffuse large B-cell lymphoma. (ekstern lenke)
• Kathrine Thuestad Isaksen; Renate Berget Galleberg; Maria Adele Mastroianni et al. (2023). The Geriatric Prognostic Index: a clinical prediction model for survival of older diffuse large B-cell lymphoma patients treated with standard immunochemotherapy. (ekstern lenke)
• Sigrid Lunde; Einar Klæboe Kristoffersen; Dipak Sapkota et al. (2016). Serum BAFF and APRIL levels, T-lymphocyte subsets, and immunoglobulins after B-cell depletion using the monoclonal anti-CD20 antibody rituximab in myalgic encephalopathy/chronic fatigue syndrome. (ekstern lenke)
• Knut Halvor Bjøro Smeland; Cecilie E. Kiserud; Grete Fossum Lauritzsen et al. (2015). Conditional survival and excess mortality after high-dose therapy with autologous stem cell transplantation for adult refractory or relapsed Hodgkin lymphoma in Norway. (ekstern lenke)
• Knut Bjøro Smeland; Cecilie E. Kiserud; Grete Fossum Lauritzsen et al. (2016). A national study on conditional survival, excess mortality and second cancer after high dose therapy with autologous stem cell transplantation for non-Hodgkin lymphoma. (ekstern lenke)
• Knut Bjøro Smeland; Jon Håvard Loge; Hans Christian Dalsbotten Aass et al. (2018). Chronic fatigue is highly prevalent in survivors of autologous stem cell transplantation and associated with IL-6, neuroticism, cardiorespiratory fitness, and obesity. (ekstern lenke)
• Mette Pernille Myklebust; Øystein Fluge; Heike Immervoll et al. (2012). Expression of DSG1 and DSC1 are prognostic markers in anal carcinoma patients. (ekstern lenke)
• Maare Arffman; Leo Meriranta; Matias Autio et al. (2024). Inflammatory and subtype-dependent serum protein signatures predict survival beyond the ctDNA in aggressive B cell lymphomas. (ekstern lenke)
• Kjersti Lia; Rasmus Rask Kragh Jørgensen; Per Wikman et al. (2025). A simplified frailty score predicts outcome in curatively treated older patients with classical Hodgkin lymphoma. (ekstern lenke)
• Ingemar Lagerlöf; Harald Holte; Ingrid Glimelius et al. (2019). No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy. (ekstern lenke)
• Hanne Skjerven Bersvendsen; Hege Sagstuen Haugnes; Alv A Dahl et al. (2020). Sexual dysfunction is prevalent in female lymphoma survivors after autologous stem-cell transplantation and is associated with younger age, chronic fatigue, and mental distress. (ekstern lenke)
• Erling Dahl Borkamo; Øystein Fluge; Olav Mella et al. (2008). Hyperthermia improves the antitumour effect of metronomic cyclophosphamide in a rat transplantable brain tumour. (ekstern lenke)
• Elisabeth Kjelsvik Steinsvik; Trygve Hausken; Øystein Fluge et al. (2023). Gastric dysmotility and gastrointestinal symptoms in myalgic encephalomyelitis/chronic fatigue syndrome. (ekstern lenke)
• Ove Bruland; Øystein Fluge; Heike Immervoll et al. (2008). Gene expression reveals two distinct groups of anal carcinomas with clinical implications. (ekstern lenke)
• Ingrid Gurvin Rekeland; Øystein Fluge; Kine Alme et al. (2018). Rituximab serum concentrations and anti-rituximab antibodies during B-cell depletion therapy for myalgic encephalopathy/chronic fatigue syndrome. (ekstern lenke)
• Kristin Marie Knudsen-Baas; Gunnar Moen; Øystein Fluge et al. (2013). Pseudoprogression in high-grade glioma. (ekstern lenke)
• Sari Riihijärvi; Heidi Nurmi; Harald Holte et al. (2012). High serum vascular endothelial growth factor level is an adverse prognostic factor for high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapy. (ekstern lenke)
• Ina Katrine Nitschke Pettersen; Deusdedit Tusubira; Hanan Ashrafi et al. (2019). Upregulated PDK4 expression is a sensitive marker of increased fatty acid oxidation. (ekstern lenke)
• Gregor Dresemann; Michael Weller; Mark A. Rosenthal et al. (2010). Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. (ekstern lenke)
• Olav Dahl; Erling Dahl Borkamo; Øystein Fluge (2008). Current status of antivascular therapy and targeted treatment in the clinic. (ekstern lenke)
• Maria Pia Giannoccaro; Judith Cossins; Kari Sørland et al. (2019). Searching for Serum Antibodies to Neuronal Proteins in Patients With Myalgic Encephalopathy/Chronic Fatigue Syndrome. (ekstern lenke)
• Erling Dahl Borkamo; Olav Dahl; Ove Bruland et al. (2009). Kinetics study on markers of the immune system by gene expression profiling of an in vivo heated tumor. (ekstern lenke)
• Øystein Fluge; Ingrid Gurvin Rekeland; Kari Sørland et al. (2025). Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study. (ekstern lenke)
• Mette Pernille Myklebust; Zhiping Li; Thai H. Tran et al. (2012). Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer. (ekstern lenke)
• Cecilie E. Kiserud; Unn-Merete Fagerli; Knut Bjøro Smeland et al. (2016). Pattern of employment and associated factors in long-term lymphoma survivors 10 years after high-dose chemotherapy with autologous stem cell transplantation. (ekstern lenke)
• Hanne Skjerven Bersvendsen; Hege Sagstuen Haugnes; Alv A Dahl et al. (2019). Sexual function in long-term male lymphoma survivors after high-dose therapy with autologous stem-cell transplantation. (ekstern lenke)
• Alexander Fosså; Knut Bjøro Smeland; Øystein Fluge et al. (2020). Metabolic analysis of amino acids and vitamin B6 pathways in lymphoma survivors with cancer related chronic fatigue. (ekstern lenke)
• Miriam Kristine Sandvik; Kari Sørland; Elisabeth Leirgul et al. (2023). Endothelial dysfunction in ME/CFS patients. (ekstern lenke)
• Asgeir Lande; Øystein Fluge; Elin Bolle Strand et al. (2020). Human Leukocyte Antigen Alleles Associated With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). (ekstern lenke)
• Øystein Fluge; Ove Bruland; Lars A. Akslen et al. (2006). Gene expression in poorly differentiated papillary thyroid carcinomas. (ekstern lenke)
• Kjersti Lia; Rasmus R.K. Jørgensen; Bente Loftum Wold et al. (2023). Overall survival and causes of death in elderly patients with Hodgkin lymphoma: a Norwegian population-based case-control study. (ekstern lenke)
• Olav Dahl; Øystein Fluge; Erik Carlsen et al. (2009). Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group. (ekstern lenke)
• Øystein Fluge; K Gravdal; E Carlsen et al. (2009). Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis. (ekstern lenke)
• Madlen Loebel; Patricia Grabowski; Harald Heidecke et al. (2016). Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome. (ekstern lenke)
• Sirpa Leppä; Judit Jørgensen; Anne Tierens et al. (2020). Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis. (ekstern lenke)
• Mette Pernille Myklebust; Ove Bruland; Øystein Fluge et al. (2011). MicroRNA-15b is induced with E2F-controlled genes in HPV-related cancer. (ekstern lenke)
• Ingrid Gurvin Rekeland; Kari Sørland; Ove Bruland et al. (2022). Activity monitoring and patient-reported outcome measures in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome patients. (ekstern lenke)
• Riad Hajdarevic; Asgeir Lande; Jesper Mehlsen et al. (2022). Genetic association study in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) identifies several potential risk loci. (ekstern lenke)
• Donia Jamal Ramadan; Katherine M. Kichula; Sudan Tao et al. (2025). Killer cell immunoglobulin-like receptor (KIR) alleles suggested to be associated with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). (ekstern lenke)
• Knut Bjøro Smeland; Harald Holte; Unn-Merete Fagerli et al. (2022). Total late effect burden in long-term lymphoma survivors after high-dose therapy with autologous stem-cell transplant and its effect on health-related quality of life. (ekstern lenke)
• Knut Bjøro Smeland; Cecilie E. Kiserud; Grete Fossum Lauritzsen et al. (2013). Høydosebehandling med autolog stamcellestøtte ved lymfom i Norge 1987 - 2008. (ekstern lenke)
• Fredrik Hoel; August Hoel; Ina Katrine Nitschke Pettersen et al. (2021). A map of metabolic phenotypes in patients with myalgic encephalomyelitis/chronic fatigue syndrome. (ekstern lenke)
• Ingrid Gurvin Rekeland; Alexander Fosså; Asgeir Lande et al. (2020). Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study. (ekstern lenke)
• Marthe Ueland; Riad Hajdarevic; Olav Mella et al. (2022). No replication of previously reported association with genetic variants in the T cell receptor alpha (TRA) locus for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). (ekstern lenke)
• Øystein Fluge; Ove Bruland; Kristin Risa et al. (2011). Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study. (ekstern lenke)
• Øystein Fluge; Ingrid Gurvin Rekeland; Katarina Lien et al. (2019). B-lymphocyte depletion in patients with myalgic encephalomyelitis/chronic fatigue syndrome: A randomized, double-blind, placebo-controlled trial. (ekstern lenke)
• Sirpa Leppä; Leo Meriranta; Maare Arffman et al. (2025). Biomarker-adapted treatment in high-risk large B-cell lymphoma. (ekstern lenke)
• Oliver P Gunther; Jennifer L Gardy; Phillip Stafford et al. (2018). Immunosignature Analysis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). (ekstern lenke)
• Knut Halvor Bjøro Smeland; Cecilie E. Kiserud; Grete Fossum Lauritzsen et al. (2013). High dose therapy with autologous stem cell support for lymphoma in Norway 1987-2008. (ekstern lenke)
• Victoria C Simensen; Knut Bjøro Smeland; Cecilie E. Kiserud et al. (2019). Survivors' knowledge of their diagnosis, treatment and possible late adverse effects after autologous stem cell transplantation for lymphoma. (ekstern lenke)
• Marianne Brodtkorb Eide; Grete Fossum Lauritzsen; Gunnar Kvalheim et al. (2011). High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas. A Norwegian multi centre phase II study. (ekstern lenke)
• Øystein Fluge; Ernst Omenaas; Geir Egil Eide et al. (1998). Fish consumption and respiratory symptoms among young adults in a Norwegian community. (ekstern lenke)
• Ingrid Gurvin Rekeland; Kari Sørland; Lisbeth Lykke Neteland et al. (2024). Six-year follow-up of participants in two clinical trials of rituximab or cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. (ekstern lenke)
• Line Bjorland; Rupavathana Mahesparan; Øystein Fluge et al. (2023). Impact of extent of resection on outcome from glioblastoma using the RANO resect group classification system: a retrospective, population-based cohort study. (ekstern lenke)
• Riad Hajdarevic; Asgeir Lande; Ingrid Gurvin Rekeland et al. (2021). Fine mapping of the major histocompatibility complex (MHC) in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) suggests involvement of both HLA class I and class II loci. (ekstern lenke)
• Line Bjorland; Kathinka Dæhli Kurz; Øystein Fluge et al. (2022). Butterfly glioblastoma: Clinical characteristics, treatment strategies and outcomes in a population-based cohort. (ekstern lenke)
• Øystein Fluge; Kristin Risa; Sigrid Lunde et al. (2015). B-lymphocyte depletion in myalgic encephalopathy/chronic fatigue syndrome. An open-label phase II study with rituximab maintenance treatment. (ekstern lenke)

Leserbrev

• Karl Johan Tronstad; Øystein Fluge; Olav Mella (2017). Chronic fatigue syndrome and pyruvate dehydrogenase function.. (ekstern lenke)
• Elisa Jacobsen Pulczynski; Mikkel Runason Simonsen; Outi Kuittinen et al. (2024). Elderly long-term survivors in the Nordic phase II study with first-line maintenance temozolomide for primary central nervous system lymphoma: a 10-year follow-up. (ekstern lenke)
• F. Pauly; K. Fjordén; S. Leppä et al. (2016). Plasma immunoprofiling of patients with high-risk diffuse large B-cell lymphoma: a Nordic Lymphoma Group study. (ekstern lenke)
• Kjersti Lia; Rasmus Rask Kragh Jørgensen; Per Wikman et al. (2025). Response to Comment on: “A simplified frailty score predicts outcome in curatively treated older patients with classical Hodgkin lymphoma”. (ekstern lenke)
• Karl Johan Tronstad; Øystein Fluge; Olav Mella (2018). Kronisk utmattelsessyndrom og pyruvat dehydrogenasefunksjon. (ekstern lenke)
• Karl Johan Tronstad; Øystein Fluge; Katarina Lien et al. (2017). Mer om pyruvat dehydrogenase og kronisk utmattelsessyndrom.. (ekstern lenke)

Doktorgradsavhandling

• Øystein Fluge (2004). Gene expression in papillary thyroid carcinomas, with special reference to tyrosine kinase receptors and growth factors. (ekstern lenke)

Konferanseabstrakt

• Harald Holte; Sirpa Leppä; Magnus Björkholm et al. (2010). R-CHOEP-14 x 6 Followed by Systemic CNS Prophylaxis for Diffuse Large B-Cell Lymphoma/Follicular Lymphoma Grade 3 with Age Adjusted IPI Score 2-3: Final Results of a Nordic Lymphoma Group Phase 2 Study Including 156 Patients Aged 18-65 Years. (ekstern lenke)
• Sari Riihijärvi; Heidi Nyman; Harald Holte et al. (2010). High Serum Vascular Endothelial Growth Factor (VEGF) Level Is An Adverse Prognostic Factor In High Risk Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Dose-Dense Chemoimmunotherapy and Systemic CNS Prophylaxis. Results From a Nordic Phase II Study. (ekstern lenke)
• Satu Koivula; Minna Taskinen; Ping Chen et al. (2010). Exon Based Transcriptome Profiling Reveals Genes That Have Prognostic Impact on the Survival of Young High Risk Diffuse Large B Cell/Follicular Grade 3 Lymphoma Patients Treated with Dose-Dense Chemoimmuno-therapy and CNS Prophylaxis. Results From a Nordic Lymphoma Group Phase II Study. (ekstern lenke)
• Sirpa Leppä; Minna Taskinen; Satu Koivula et al. (2012). Use of exon-based transcriptome profiling to identify novel signaling pathways and survival-associated genes in diffuse large B-cell lymphoma. (ekstern lenke)
• Harald Holte; Trond Bogsrud; S. Leppa et al. (2011). (18)FDG PET/CT AFTER INTENSIFIED CHEMO-IMMUNOTHERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), AGED 18-65 YEARS WITH AAIPI 2-3. POSITIVE OR INDETERMINATE LESIONS HAVE A LOW POSITIVE PREDICTIVE VALUE. A NORDIC PHASE II SUBSTUDY. (ekstern lenke)
• Satu Koivula; Minna Taskinen; Ping Chen et al. (2010). Exon-Based Transcriptome Profiling Reveals Genes That Have Prognostic Impact on the Survival of Young High Risk Diffuse Large B-Cell/Follicular Grade 3 Lymphoma Patients Treated with Dose-Dense Chemoimmuno-therapy and CNS Prophylaxis. Results From a Nordic Lymphoma Group Phase II Study. (ekstern lenke)

Vitenskapelig litteraturgjennomgang

• Sophie Steiner; Annick Fehrer; Friederike Hoheisel et al. (2023). Understanding, diagnosing, and treating Myalgic encephalomyelitis/chronic fatigue syndrome – State of the art: Report of the 2nd international meeting at the Charité Fatigue Center. (ekstern lenke)
• Øystein Fluge; Karl Johan Tronstad; Olav Mella (2021). Pathomechanisms and possible interventions in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). (ekstern lenke)
• Olav Dahl; Øystein Fluge (2008). Analkreft. (ekstern lenke)

Vitenskapelig bokkapittel

• Thoralf Christoffersen; Øystein Fluge; Gustav Lehne et al. (2009). Kreftceller og kjemoterapi. (ekstern lenke)
• Johan Lillehaug; Øystein Fluge; Jan Erik Varhaug (2006). Thyroid Cancer: Molecular Biology and Clinical Aspects. (ekstern lenke)

Kapittel i fagbok

• Thoralf Christoffersen; Øystein Bruserud; Øystein Fluge et al. (2016). Kreftbiologi og medikamentell terapi. (ekstern lenke)

Vitenskapelig kommentar

• Karl Johan Tronstad; Øystein Fluge; Olav Mella (2018). Kronisk utmattelsessyndrom og pyruvat dehydrogenasefunksjon.. (ekstern lenke)

Se en full oversikt over publikasjoner i Cristin